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Abstract Histone modifications have widely been impli-
cated in cancer development and progression and are
potentially reversible by drug treatments. The N-terminal
tails of each histone extend outward through the DNA
strand containing amino acid residues modified by post-
translational acetylation, methylation, and phosphorylation.
These modifications change the secondary structure of the
histone protein tails in relation to the DNA strands,
increasing the distance between DNA and histones, and
thus allowing accessibility of transcription factors to gene
promoter regions. A large number of HDAC inhibitors have
been synthesized in the last few years, most being effective
in vitro, inducing cancer cells differentiation or cell death.
The majority of the inhibitors are in clinical trials, unlike
the suberoylanilide hydroxamic acid, a pan-HDACi, and
Romidepsin (FK 228), a class I-selective HDACi, which
are only approved in the second line treatment of refractory,
persistent or relapsed cutaneous T-cell lymphoma, and
active in approximately 150 clinical trials, in monotherapy
or in association. Preclinical studies investigated the use of
these drugs in clinical practice, as single agents and in
combination with chemotherapy, hypomethylating agents,
proteasome inhibitors, and MTOR inhibitors, showing a
significant effect mostly in hematological malignancies.
The aim of this review is to focus on the biological features
of these drugs, analyzing the possible mechanism(s) of
action and outline an overview on the current use in the
clinical practice.
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Histones: structure and functions
Histones are alkaline proteins found in eukaryotic cell
nuclei, which package and order the DNA into structural
units called nucleosomes. They can be grouped into five
major classes: H1/H5, H2A, H2B, H3, and H4. These are
organized into two super-classes: core histones, H2A, H2B,
H3, and H4 and linker histones, H1 and H5. Two core
histones assemble to form one octameric nucleosome core
particle by wrapping DNA around the protein spool in
1.65 Å left-handed super-helical coil. The linker histone H1
binds the nucleosome and the entry and exit sites of the
DNA, thus locking the DNA into place and allowing the
formation of higher order structure. A typical nucleosome is
composed of an octamer of the four pairs of core histones
H2A, H2B, H3, and H4 and ≈146 base pairs of DNA
wrapped around. Histones undergo posttranslational mod-
ifications altering their interaction with DNA and nuclear
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Epigenetic modifications of the histone proteins
The H3 and H4 histones have long tails protruding from the
nucleosome, which can be covalently modified. The core of
H2A and H3 is susceptible as well. These modifications
include methylation, phosphorylation, sumoylation, citrulli-
nation, acetylation, and ubiquitination. Combinations of
modifications are thought to constitute the so-called
“histone code.” Diverse biological processes such as gene
regulation, DNA repair, and chromosome condensation
seem to be regulated by this code.
Methylation
The addition of one, two, or three methyl groups is generally
associated with transcriptional repression. However, methyl-
ation of some lysine and arginine by residues of histones,
results in transcriptional activation. Methylation is operated
by histone methyltransferases enzymes, histone-lysine N-
methyltransferase and histone-arginine N-methyltransferase:
both catalyze the transfer of one to three methyl groups from
the co-factor S-adenosyl methionine to lysine and arginine
residues of histone proteins. Methylation of histone 3 (H3) at
lysine 4 (K4)isalsoassociatedwith transcriptional activation,
whereas methylation of H3 at K9 or 27 and of H4 at K20 is
associated with transcriptional repression (Cameron et al.
1999;E s t e l l e r2008; Kondo et al. 2008).
Phosphorylation
Relatively little is known about the enzymes that generate
histone modifications. Phosphorylation of serine 10 in
histone H3 has been shown to correlate with gene
activation in mammalian cells (Nowak and Corces 2000).
The mechanism by which phosphorylation contributes to
transcriptional activation is not well understood. The
addition of negatively charged phosphate groups to histone
tails neutralizes their basic charge reducing their affinity for
DNA. Furthermore, it has been found that several acetyl-
transferases have increased HAT activity on serine 10-
phosphorylated substrates. Thus, phosphorylation may
contributetotranscriptional activationthroughthe stimulation
of HAT activity on the same histone tail. Phosphorylation
of histone H3 is also known to occur after activation of
DNA damage signaling pathways. For example, a
conserved motif found in the carboxyl terminus of yeast
H2A and the mammalian H2A variant H2AX is rapidly
phosphorylated upon exposure to DNA-damaging agents
(Rogakou et al. 1999).
Serine 139 has been identified as the site for this
modification, and its phosphorylation in response to
damage is dependent on the phosphatidylinositol-3-OH
kinase, and again serine 10 appears to play a key role
(Cheung et al. 2000). Mec1, in yeast, Mec1-dependent
serine 139 phosphorylation is apparently required for
efficient non-homologous end-joining repair of DNA
(Rogakou et al. 2000). This suggests that phosphorylation
mediates an alteration of chromatin structure, which in turn
facilitates repair.
Sumoylation
Histone H4 is modified by small ubiquitin-related modifier
(SUMO) family proteins both in vivo and in vitro. H4
binds to the SUMO-conjugating enzyme and mediates gene
silencing through recruitment of histone deacetylase and
heterochromatin proteins (Shiio and Eisenman 2003).
Citrullination
Peptidylarginine deiminase (PAD) enzymes catalyze the
conversion of arginine residues in proteins to citrulline
residues. Citrulline is a non-standard amino acid that is not
incorporated into proteins during translation, but can be
generated posttranslationally by the PAD enzymes. One
protein isozyme responsible for this modification, protein
arginine deiminase 4 (PAD4), has also been proposed to
“reverse” epigenetic histone modifications made by the
protein arginine methyltransferases (Denis et al. 2009).
Acetylation
The core histone N-terminal domains are rich in positively
charged basic amino acids, which can actively interact with
DNA. Acetylation neutralizes the positive charges on
histones and disrupts the electrostatic interactions between
DNA and histone proteins, promoting chromatin unfolding
which has been associated with gene expression (Gregory
et al. 2001). Under physiological conditions, chromatin
acetylation is regulated by the balanced action of histone
acetyltransferases (HATs) and deacetylases (HDACs). The
HATs transfer acetyl groups from acetyl coenzyme A
onto the amino groups of conserved lysine residues
within the core histones. Acetylation can neutralize the
positive charge of histones, loosening their interactions
with the negatively charged DNA backbone, and leading
to a more “open” active chromatin structure favoring the
binding of transcription factors for active gene transcrip-
tion (Gregory et al. 2001).
In contrast, the re-establishment of the positive charge in
the amino terminal tails of core histones catalyzed by
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histones and DNA, blocking the binding sites on promoter,
thus inhibiting gene transcription. Obviously, a subtly
orchestrated balance between the actions of HATs and
HDACs is essential to the maintenance of normal cellular
functions, shifting this balance in both senses might have
dramatic consequences on the cell phenotypes such as
carcinogenesis.
Ubiquitination
Ubiquitination represents another important histone modi-
fication (Jason et al. 2002). Histone H2A, the first protein
identified to be ubiquitinated at the highly conserved residue,
Lys 119 (Nickel and Davie 1989), can be monoubiquitinated,
in the majority of the cases and polyubiquitinated, less
frequently, in many tissues and cell types (Nickel and Davie
1989). In addition to H2A, H2B is also ubiquitinated (West
and Bonner 1980). Only monoubiquitinated H2B has been
reported, but like H2A, the ubiquitinated site has also been
mapped to Lys 120 residue located at the C terminus of H2B
in human. In addition to H2A and H2B, ubiquitination on
H3 and H1 have also been reported (Chen et al. 1998; Pham
and Sauer 2000).
Addition of a ubiquitin moiety to a protein involves the
sequential action of E1, E2, and E3 enzymes. Removing
the ubiquitin moiety, on the other hand, is achieved through
the action of enzymes called isopeptidases (Wilkinson 2000).
Accumulating evidence indicates that ubiquitin plays an
important role in regulating transcription either through
proteasome-dependent destruction of transcription factors or
proteasome-independent mechanisms (Conaway et al. 2002).
Several studies suggest that not only histone ubiquitination
(Krogan et al. 2003), but also deubiquitination (Henry et al.
2003), may participate in gene activation, linked to histone
acetylation and methylation (Dover et al. 2002).
Histone deacetylases
In the 1970s, the Friend erythroleukemia cell line was
found to differentiate in the presence of dimethyl sulfoxide
or butyrate (Sato et al. 1971). Many compounds with the
ability to promote differentiation of tumor cell lines,
particularly those with a planar-polar configuration, induced
accumulation of hyperacetylated histones.
This histone modification increased the spatial separa-
tion of DNA from histone and enhanced binding of
transcription factor complexes to DNA (Lee et al. 1993).
The first mammalian HDACs were cloned on the basis of
their binding to known small molecule inhibitors of histone
deacetylation. These genes were homologous to yeast
transcriptional repressors, strengthening the evidence that
histone deacetylation suppresses gene expression.
HDACs are a class of enzymes that remove acetyl groups
from a ε-N-acetyl lysine amino acid on a histone. Contrarily
to HAT, HDAC proteins are now also being referred to as
lysine deacetylases (KDAC), as to more precisely describe
their function rather than their target, which also includes
numerous non-histone proteins. Eighteen human HDACs
have been identified each with varying function, localization,
and substrates (Table 2; Lane and Chabner 2009).
Classes of HDACs
HDACs can be divided in four different classes, based on
the homologies between human and yeast reduced potassium
dependency 3 (RPD3)e n z y m e s .
Class I HDACs (HDACs 1, 2, 3, and 8) are related to
the yeast RPD3 deacetylase and are primarily found in
the nucleus with the exception of HDAC 3, which can be
located both in the nucleus and the cytoplasm.
Class II HDACs are divided into two subclasses, class
IIa (HDACs 4, 5, 7, and 9) and class IIb (HDACs 6
and 10), both homologous to the yeast Hda1 deacetylase.
This class of HDACs is able to shuttle in and out of the
nucleus responding to different signals.
Class III HDACs consists of seven HDACs (SIRT1 to
SIRT7) and shows several homologies with the yeast silent
information regulator 2. This class of HDACs has a unique
catalytic mechanism requiring the co-factor NAD+ for
activity.
Class IV of HDACs has only one member (Butler and
Kozikowski 2008), HDAC 11, which shares similarities to
both class I and class II HDACs.
Classes I, II, and IV require Zn
2+ for activity.
Catalytic site and deacetylation mechanism
Histone proteins catalytically remove an acetyl group from
a ε-N-acetyl lysine amino acid on a histone. The active site
of HDACs consists of a cylindrical pocket, covered by
hydrophobic and aromatic amino acids, where the lysine
residue fits when deacetylation takes place; a zinc ion is
located near the bottom of the cylindrical pocket, which is
coordinated by amino acids and a single water molecule
(Butler and Kozikowski 2008). During deacetylation, the
water molecule acts as the nucleophile attacking the
carbonyl, assisted by the zinc ion (Fig. 1). Prior to attacking
the carbonyl group of the N-acetylated lysine, the water
molecule is activated by an Asp–His charge relay system.
The residues forming the cylindrical pocket and the
adjacent cavity of classes I and II HDACs are highly
conserved, although the residues lining the entrance of the
Clin Epigenet (2010) 1:25–44 27pocket are not as conserved as the residues inside the
pocket. Therefore, it is possible to design HDAC inhibitors
(HDACis) that are isoform selective.
HDAC expression in cancer tissues
Evidence has shown an implication of HDACs in cancer, as
the high expression of HDAC isoenzymes correspond to
hypoacetylation of histones in cancer cells compared to
normal tissues (Nakata et al. 2004; Yoo and Jones 2006):
HDAC 1 enzyme expression is higher in colon adenocar-
cinoma cells than in normal, while HDAC 2 expression is
elevated in colon cancer, possibly as a result of adenoma-
tosis poliposis coli gene deficiency.
A study conducted by Nakagawa showed a hyper
expression of HDACs in a variety of cultured cancer lines
and a broad panel of primary human lung, esophageal,
gastric, colon, pancreas, breast, ovary, and thyroid cancers
(Nakagawa et al. 2007).
High level class I HDAC expression was found in 75%
esophageal, gastric, colon, and prostate cancers, as well as
corresponding adjacent “normal” tissues. Esophageal and
prostate cancers tended to exhibit more consistent over-
expression of class I HDACs. Further studies suggest a
correlation between advanced stage of lung carcinoma and
high expression of class 1 HDAC 1 (Sasaki et al. 2004), as
well as aggressive tumor histology, advanced stage of
disease, and poor prognosis in patients with pancreatic
carcinoma (Miyake et al. 2008).
Several retrospective studies, conducted on colon cancer
primary cells, showed high level expression of HDAC 1
and 2 in gastric cancer; the higher expression correlated
with nodes metastasis, undifferentiated histology, and poor
prognosis (Weichert et al. 2008). High level expression of
HDAC 1, 2, and 3 was observed in 70%, 74%, and 95% of
192 prostate cancers in a related study, where overexpres-
sion of HDAC 1 and/or HDAC 2 correlated with poorly
differentiated tumors. Co-expression of elevated levels of
the three HDACs was associated to an increased prolifer-
ation index, while overexpression of HDAC 2 alone was an
independent index of poor prognosis.
Overexpression of HDAC 2 also correlates with advanced
stage of disease and diminished survival of oropharyngeal
carcinoma patients (Chang et al. 2009). In contrast, HDAC 1
expression in breast cancer is associated with estrogen
receptor/progesterone (PR) expression at the earlier stage of
disease (T as well as N classifications) and improved patient
survival response to tamoxifen (Bicaku et al. 2008), and
HDAC 6 expression is associated to improved patient
survival (Zhang et al. 2004).
HDAC expression in hematological malignancies
In hematological malignancies, increased HDAC activity
may lead to transcriptional repression of genes essential for
hematopoietic differentiation, playing a critical role in the
pathogenesis of several leukemias. In the case of acute
promyelocytic leukemia (APL), the PML-RARα protein
product of the t(15–17) translocation, and in core binding
factor leukemia gene products AML1–ETO, product of the
t(8–21) translocation and CBF–MYH 11, cause a transcrip-
tional repression, aberrantly recruiting HDACs to genes
promoter regions (Minucci and Pelicci 1999); (Minucci
et al. 2001). CTCL cells undergo higher rates of apoptosis
than normal lymphocytes in response to HDAC inhibitor
treatment (Zhang et al. 2005). Sodium butyrate and
tricostatin A induced apoptosis of acute myeloid leukemia
(AML; HL60) and CML (K562) cell line, downregulating
the expression of Daxx, without affecting the expression of
Bcl-2 or Bcl-XL. A recent study reports anti-leukemic
Fig. 1 Water molecule acting as the nucleophile prior and during the
attack of carbonyl, assisted by the zinc ion
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CLL primary cells obtained from 14 patients (Stamatopoulos
et al. 2009).
These findings supported drug development of HDACi
that interacting with the catalytic region of HDACs, block
HDAC activity, induce differentiation, cell growth arrest, or
cell death in tumors (Mai et al. 2005; Nebbioso et al. 2005).
Histone deacetylase inhibitors
HDACis are compounds that are able to interact with the
catalytic domainofhistone deacetylases toblock the substrate
recognition ability of these enzymes, thus resulting in
restoration of relevant gene expression (Finnin et al. 1999).
The vast majority of HDACis shares a common
mechanism of action that consists with binding the catalytic
domain of HDAC enzyme, thereby blocking substrate
recognition and inducing gene expression. Most of the
described HDACis primarily affect class I and class II
HDACs, which are zinc dependent.
HDACis can be divided into four classes based on
different chemical properties: short-chain fatty acids,
hydroxamic acids, cyclic peptides, and benzamides (Table 1).
Short-chain fatty acids
This group includes Na butyrate, 4-phenylbutyrate, valproic
acid, and phenyl acetate. The mechanism of action has not
been well clarified yet, although a strong hypothesis exists
in which the carboxylic function acts as zinc-binding group
or competes with the acetate released in the deacetylation
reaction by occupying the acetate escaping tunnel as
described by Wang (Mai and Altucci 2009).
The butyrates (Na butyrate and 4 phenylbutyrate) inhibit
the growth of several cancers, such as colon prostate and
endometrial, but just at high concentration; although they
both show effects on phosphorylation and methylation of
histone and other nuclear proteins.
Sodium valproate (valproic acid, VPA), an “old” drug
used in neurology as anticonvulsive and mood stabilizing,
has been incidentally identified as HDACi and has shown
anticancer effects in carcinoma cells, differentiation in
hematopoietic cell lines, and also in clinical trials for
hematological malignancies, such as leukemia, myelodys-
plastic syndrome (MDS), and lymphoma. VPA inhibits
class I/IIa HDACs at very low concentrations compared to
butyrates (Mai and Altucci 2009).
Hydroxamic acids
This class includes the majority of HDACis presently in use
in clinical trials in hematological malignancies. They have a
common structure characterized by a hydrophobic CAP
group, able to interact with the rim of the catalytic tunnel of
the enzyme, a polar connection unit (CU). Present in most
of the HDACis, the CU can interact with the amino acids in
the tunnel, and a 4- or 6-carbon unit hydrophobic spacer
(linker), allowing the following zinc-binding group (ZBG)
Table 1 Histone deacetylases
Class HDAC HDACs yeast HDACs mammalian Length Mechanism of deacetylation Tissue expression
Class I RPD3 HDAC1 482 Zn
2+ dependent Ubiquitous
HDAC2 488
HDAC3 428
HDAC8 377
Class II HDA1 HDAC4 1084 Zn
2+ dependent Restricted
HDAC5 1122
HDAC6 1215
HDAC7 912
HDAC9 1011
HDAC10 669
Class III SIR2 SIRT1 747 NAD
+ dependent ND
HST1 SIRT2 373
HST2 SIRT3 399
HST3 SIRT4 314
HST4 SIRT5 310
SIRT6 355
SIRT7 400
Class IV RPD3 HDAC11 347 Zn
2+ dependent Ubiquitous
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enzyme (Mai et al. 2005).
Past reports of the hydroxamic acid tricostatin A, first
isolated as antifungal antibiotic (Tsuji et al. 1976), indicated
the capacity of this drug to differentiate the Friend
erythroleukemia cells. Further experiments have shown
that the compound caused hyperacetylation due to hystone
deacetylation inhibition.
The hybrid polar compounds (HPCs) are potent inducers
of differentiation of murine erythroleukemia cells and a
various other cancer cells (Andreeff et al. 1992; Mai et al.
2005). The progenitor of these compounds was hexam-
ethylene bisacetamide, a drug that is able to induce
remission in patients with myelodysplastic syndrome and
acute myeloid leukemia, but cannot be used in clinical trials
for the high dosage required and adverse side effects. The
second generation of HPCs has shown a strong induction of
apoptosis or cell differentiation at low doses (Mai and
Altucci 2009).
The prototype of this class is the suberoylanilide
hydroxamic acid (SAHA or Vorinostat). The chemical
structure of SAHA is similar to VPA and the others, HPCs,
with a CAP, a CU, and a ZBG. It has shown to induce
acetylation in a vast variety of cell line and apoptosis, cell
cycle arrest, and differentiation. SAHA is selective for
HDAC 1, 2, 3, 4, 6, 7, and 9 and shows lower potency
against HDAC 8.
In October 2006 the US FDA, approved SAHA in the
therapy of refractory, relapsed cutaneous T-cell lymphoma
(CTCL) and is at the present involved in a vast variety of
clinical trials both in hematological malignancies, such as
leukemia, MDS, lymphoma and myeloma, and solid
tumors. The mechanism of action is still unclear because
of the involvement of many pathways, including apoptosis,
autophagy, and induction of ROS and DNA damage repair,
all of them subsequent to re-expression of genes that
become accessible to transcription factors, when hystone
proteins are in an acetylated status.
The clinicalefficacyofSAHA inspiredthe development of
new analogues of the same class, as the indolyethylamino-
methylcinnamyl hydro-amides LAQ-824 and LBH 589
(panobinostat; Arts et al. 2007).
Panobinostat, as SAHA, is in a vast variety of phase II/III
clinical trials, both in solid tumors and hematological
malignancies, such as lymphomas, multiple myeloma,
MDS, acute myeloid leukemia, and CML. Its HDAC
inhibition is strong against class I HDACs and less
potent against class IIa.
Belinostat (PXD101) is a hydroxamic acid derivative,
which has been administered as an infusion on days 1 to
5 of a 21-day cycle in a phase I study in patients with
advanced B-cell malignancies refractory to standard
therapy.
Cyclic peptides
The cyclic peptide Romidepsin, also known as FK-228, has
been reported to induce cell cycle arrest and apoptosis in a
variety of human cancer cells. In vitro it has shown a strong
activity against HDAC 1 and 2, but also against HDAC 6
and HDAC 4, although it results to be weaker (Mai and
Altucci 2009). The drug has been in clinical trials for CML
and AML (Byrd et al. 2005; Piekarz et al. 2004) and has
been approved in November 2009 for the treatment of
refractory–relapsed CTCL (Kim et al. 2008).
Benzamides
This class of HDACis presents a different structure from
the other classes because of the 2′-aminoanilide moiety,
which can likely function as a weak zinc-chelating
group into the tube-like active site of the deacetylase
core of the enzyme as suggested by molecular modeling
studies (Wang et al. 2005), or may contact key amino
acids in the active site without Zn ion coordination.
MS-275 (entinostat) inhibits preferentially HDAC 1, 2,
and 3 and is inactive (IC50s>10 μM) against HDAC 4,
6, 7, and 8 (Khan and La Thangue 2008). In clinical
trials, it has been used in solid tumors, such as lung
and breast cancer and metastatic melanoma, and in
hematological malignancies, as CML, AML, CMML, and
Hodgkin disease.
MGCD 0103 is a more recent benzamide that shows
selectivity for HDAC I/II. It has been used in clinical trials
mostly for hematological malignancies, such as AML,
CML, non-Hodgkin lymphomas and refractory Hodgkin
disease, where it has shown very encouraging results.
SIRT inhibitors
The compounds of this class of HDACis (class III) are
much less validated as anticancer agents compared to
HDAC I and II. This is also due to the fact that a low
number of preclinical in vivo data exist presently and a
small number of inhibitors are on the market.
Sirtuins play an important role in many cellular
processes such as gene silencing and regulation of
transcription factors. Members of the sirtuin family of
NAD
+-dependent protein deacetylases SIRT1 controls cell
differentiation, metabolism, circadian rhythms, stress
responses, and cellular survival. When tested in the human
leukemia U937 cell line, SIRT inhibitors displayed high
levels of apoptosis and cyto-differentiation. SIRT1 binds
and deacetylates the histone acetyltransferase p300, which
inhibits p300 enzymatic activity, which has the potential to
promote hypoacetylation of nucleosomal histones and
affect gene expression outcomes (Zhang et al. 2009).
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that induces apoptosis in BCL-6 expressing Burkit lym-
phoma cells, through acetylation of both BCL-6 and p53
(Heltweg et al. 2006). Finally, the anticancer action of SIRT
inhibitors has been also reported to act via reactivation of
methylated genes without evident DNA demethylation at
the promoters level (Pruitt et al. 2006).
Mechanism of action
The clinical manifestation of aberrant HDAC expression is
histology dependent. Each of the HDACs have different
targets, not only interacting directly with chromatin through
the acetylation of core histones (Ozdag et al. 2006)o r
“marking” chromatin for further recruitment of chromatin
remodeling complexes (Choi and Howe 2009), such as
hormone receptors, DNA repair enzymes, and signal
transduction mediators chaperone proteins and cytoskeleton
proteins, regulating cell proliferation and cell death
(Dokmanovic and Marks 2005). Acetylation can either
increase or decrease the function or stability of the proteins
or protein–protein interaction (Glozak et al. 2005).
Gene expression
Acetylation generally results in an increase of the negative
charge on histone core leading to an uncoiled chromatin
structure, and accessibility to transcription factors of
different genes, but the final gene expression is the result
of the interaction of other alterations in chromatin structure
mediated by DNA, such histone methylation, and the
summation of activators and repressors recruited to the
respective promoters (Ellis et al. 2008). It is important to
stress that the number of genes detected with altered
transcription is strongly influenced by the time of culture
and concentration of HDACi. A short exposition and a low
concentration of HDACi are associated with fewer changes,
compared to consisting doses of the drugs and longer time
points (Ellis et al. 2008).
The gene that seems to act on of the most induced by
HDACis is a cyclin-dependent kinase, p21, which is
regulated via p53 dependent as well as p53 independent;
its expression correlates with an increase in the acetylation
of histones associated with the p21 promoter region
(Richon et al. 2000) and coincides with acetylation of
histones H3 and H4.
HDACis are also able to increase the activity of
5-azacytidine and 5-aza-2′-deoxycytidine of the expression
of suppressor gene promoters, silenced by aberrant meth-
ylation (Cameron et al. 1999). This mechanism of poten-
tiation resulted to be more complex because recent studies
suggest that TSA decreases the stability of DNMT3b
mRNA, resulting in decrease of de novo methylation in
endometrial cancer cells (Xiong et al. 2005).
Cell cycle regulation
HDACis have shown to impact the cell cycle by inducing,
at low concentrations, predominantly G1 arrest (Marks
et al. 1996) and G1 and G2/M arrest, at high concentration
(Richon et al. 1997).
Cell cycle arrest is associated with decreased expression
of cyclins A, B, and D, as well as their respective cyclin-
dependent kinases, and induction of p21 and p27 (Emanuele
et al. 2008). TSA, FK 228, deplete levels of kinethocore
proteins and decreased phosphorylation of histone H3 in
pericentrometric chromatin during G2 phase, while SAHA
inhibits the transcription of aurora kinase A and B, resulting
in apparent mitotic catastrophe (Dowling et al. 2005; Park
et al. 2008; Robbins et al. 2005).
Regulation of the apoptotic pathways
Extrinsic pathway of apoptosis is initiated by the binding of
death receptors to their ligands leading to activation of
caspase-8 and caspase-10. HDACis upregulate the expres-
sion of the death receptors, Fas (Apo-1 or CD95), tumor
necrosis factor (TNF) receptor-1 (TNFR-1), in transformed
cells, but not in normal cells (Nakata et al. 2004). TRAIL
and its receptor DR-5 were induced in the mouse model of
APL by VPA (Insinga et al. 2005); TNF-related apoptosis-
inducing ligand death receptors (DR-4 and -5) were
induced in the mouse model of APL by VPA.
The intrinsic apoptosis pathway is mediated by mito-
chondria with the release of mitochondrial inter-membrane
proteins, such as cytochrome c, apoptosis-inducing factor
Smac, and the consequent activation of caspases. It is
regulated, in part, by pro- and anti-apoptotic proteins of
bcl-2 family (Insinga et al. 2005). Activation of the intrinsic
apoptotic pathway is a major pathway for HDACis to
induce cell death utilizing mechanisms that are still not well
understood. HDACis facilitate the release of cytochrome c
from mitochondrial inter-membrane space and activation of
caspase-9 (Marks et al. 1996; Bolden et al. 2006), over-
expression of Bcl-2 or Bcl-XL, while protecting the
mitochondria, inhibit HDACi-induced apoptosis.
HDACis and autophagy
Autophagy is a mechanism of cellular proteins self-
digestion by complexes called auto-phagosomes rich in
lysosome, activated in cells during stress conditions, such
as ATP deprivation, infections, and glucose deprivation.
This mechanism of death is caspase independent and
induced by nuclear, and p73 upregulation in response to
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autophagy by inhibiting p73-mediated activation of a
variety of genes including ATG5, ATG7, and p53 that
can inhibit mTOR via activation of AMPK. Autophagy
induced by HDACis seems related to inhibition of HDAC 1
(Rosenbluth et al. 2008).
HDACis and DNA damage repair
Induction of phosphorylation of the histone variant H2AX
has been associated with the generation of double-strand
DNA. A study conducted at M.D. Anderson Cancer Center
showed that Vorinostat has the capacity to induce H2AX
phosphorylation in two different cell lines (Molt4 and
HL60). Induction of H2AX may have a role in the capacity
to induce apoptosis of these drugs. In a model of
irradiation, loss of H2AX resulted in clonogenic survival.
This data is important, suggesting that HDACis may exert
their cytotoxic effects by other mechanisms not directly
linked to histone acetylation, but perhaps DNA damage
(Sanchez-Gonzalez et al. 2006).
Induction of ROS by HDACis
Accumulation of ROS occurs in transformed cells cultured
with HDACis, such as Vorinostat, TSA, butyrate, or MS-
275 (Rosato et al. 2003; Ruefli et al. 2001; Ungerstedt et al.
2005; Xu et al. 2006). Accumulation of ROS might play an
important role in HDACi-induced cell death. ROS accu-
mulation occurs within 2 h of culture with HDACis, before
disruption of mitochondria. Free radical scavengers such as
N-acetylcysteine are able to decrease HDACi-induced
apoptosis (Ruefli et al. 2001; Ungerstedt et al. 2005).
HDACis in clinical practice
Most promising results of the in vitro studies secured
clinical trials based on the use of HDACis as single agents
or in combination with other “epidrugs” and target
therapies, or with the conventional chemotherapy either
in solid tumors and hematological malignancies with the
aim of improved response and reduced toxicity. Most
of the pilot studies, to determine the safety and the
efficacy of the compounds, have been conducted in
hematological malignancies, nearly all of them in
lymphoproliferative diseases first. The phase I clinical
trials have shown that the drugs are safe, although with
some side effects, for example cardiotoxicity that
required the suspension of the study in some cases,
and most of them are more effective in hematological
malignancies than in solid tumors for different reasons
that we will analyze later.
This review will attempt to summarize the most
significant clinical trials conducted in the last few years in
the hematological malignancies, attempting to group these
diseases in three categories: lymphomas, myelodysplastic
syndromes, and acute myelogenous leukemia and myeloma.
These drugs have been experienced in myeloproliferative
neoplasm, where encouraging results are coming out of
studies performed with Givinostat alone in Polycythemya
Vera and essential thrombocythemya (Rambaldi et al. 2008).
HDACis as single agents, the treatment of lymphoma
Lymphomas are heterogeneous diseases, with very different
biologic features and clinical outcomes. Most of the phase 1
and 2 clinical trials that explore the safety and efficacy of
HDAC inhibitors are conducted on relapse or refractory
patients and tend to group the lymphomas as the same
disease. Only subsequent studies divide the disease in
morphological clinical categories, according to the WHO
classifications. In this review, we aim to distinguish the
results obtained in T-cell lymphomas from those obtained
B-cell and Hodgkin lymphomas.
T-cell lymphomas
Lymphomas are very heterogeneous diseases, with different
biologic features and clinical outcomes. Most of the phase 1
and 2 clinical trials that explore the safety and efficacy of
HDAC inhibitors are conducted on relapsed or refractory
patients and tend to group the lymphomas as the same
disease. Only subsequent studies divide the disease in
morphological clinical categories, according to the WHO
classifications. One of the first studies in lymphomas was
conducted with Vorinostat in 35 patients with advanced
hematological malignancies (O’Connor et al. 2006). Five
patients with Hodgkin lymphoma (HL) diffused large B-
cell lymphoma (DLBCL) and cutaneous T-cell lymphoma
and experienced tumor reduction, while collateral studies
reported a transient (8 h with a peak at 2 h) increase in
histone H3 acetylation in peripheral blood mononuclear
cells. Due to the response shown in a CTCL patients treated
with oral Vorinostat, a dose-finding study was initiated in
33 patients with relapsed/refractory CTCL exploring three
different schedules of administration that showed 24%
overall response (Mann et al. 2007). A second study (Olsen
et al. 2007), which led to the Food and Drug Administration
approval of Vorinostat in CTCL, was conducted in 74
patients with stage II B or higher CTCL. This study showed
33% ORR and assessed the 400 mg/day the optimum in
terms of response/toxicity (Duvic et al. 2007). The side
effects were almost the same in the two trials, predominantly
nausea and diarrhea, while anemia and thrombocytopenia
represented the main hematologic toxicity. Further studies,
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of these drugs in CTCL and PTCL.
Panobinostat, administered orally at a MTD of 20 mg,
3 days a week on a 28-day cycle, showed to be safe and
effective, achieving complete responses, partial response,
stable disease with ongoing improvement, and progression
on treatment, respectively, in 2, 4, 2, and 1 patient.
Microarray data showed distinct gene expression response
profiles over time following panobinostat treatment, with
the majority of genes being repressed (Ellis et al. 2008). A
recent clinical trial conducted on two cohorts of patients,
previously treated with bexarotene or naïve, reported
complete skin responses in 11 out of 62 pretreated patients,
and 4 in 11 out of 33 naïve patients (Duvic et al. 2007).
Based on these results, a phase II study evaluating a
MWF schedule of panobinostat in patients with relapsed
CTCL is now ongoing (Ottmann et al. 2008).
Clinical efficacy has also been reported in a clinical trial
conducted with Belinostat in patients with relapsed in
CTCL and PTCL, showing in both diseases the same high
rate of response (25%) and disease control (50% and 72%;
Pohlman et al. 2009).
Interesting results have been reported in clinical trials
with Romidepsin as a single agent. The first study
conducted in 2001 at the National Cancer Institute reported
responses in four patients with T-cell lymphoma (Piekarz
et al. 2001). A recent analysis of a phase II study has
reported 34% of response with four CR out of 71 patients
treated with Romidepsin. The study presents a long
duration of response with a median time to progression of
15.1 months (Bates). An international multicenter study
confirmed these results in CTCL with 32% ORR and six
CR (Kim et al. 2008). Promising results have been reported
also in a Romidepsin single agent clinical trial with the
treatment of relapsed–refractory PTCL, with 31% ORR,
including four CR and 11 PR, signing the approval of the
US Food and drug Administration in the therapy of
refractory–relapsed CTCL (Piekarz et al. 2008).
B-cell and Hodgkin lymphomas
Initial encouraging results were obtained with Vorinostat
studying its effect in B-cells neoplasm, particularly
DLBCL. This study was not successful as expected from
the phase I study, given that only one patient out of 18
showed complete response (CR), while 16 patients experi-
enced progressive disease and one stable disease (SD; Crump
et al. 2008a).
In HL, Vorinostat showed a partial response in one
patient and a stable disease in nine out of 25 eligible
patients tested. A phase I/II study conducted in non-
Hodgkin lymphomas, with a schedule of 200 mg adminis-
tered twice a day for 14 days on a 21-day cycle, showed CR
in four patients, PR in two, and SD in four out of 17
patients in the study (Kirshbaum et al. 2008).
Panobinostat has been investigated in Hodgkin lympho-
mas in a phase IA/II multicenter study showing computed
tomography partial response in 5 out 13 (38%) patients
treated and a metabolic response by (18)F-fluoro-2-deoxy-
D-glucose positron emission tomography scanning in 7/12
(58%) evaluable patients (Dickinson et al. 2009).
Mocetinostat has also been tested in B-cell lymphomas
and HL. In the first case, a phase II clinical trial in patients
with relapsed–refractory, DLBCL, and follicular lymphomas
(FL) previously treated with a Rituximab-based regimen,
showed one CR and three PR in DLBCL group and 13 SD;
one patient with FL out of ten achieved a PR. Interestingly,
DLBCL patients with SD presented 6 months to 1 year PFS
(Bociek et al. 2008).
Very encouraging results have been showed in a phase II
clinical trial in relapsed–refractory HL at a dose of 85 or
110 mg, three times a week. In the 110 mg cohort, two had
CR and six PR, with a very long PFS (270–420 days); all
patients in the 85 mg cohort showed tumor reduction, with
one PR and one SD (Crump et al. 2008b). Finally, SD has
been reported in 7 out of 13 patients evaluable in a phase II
study conducted with Givinostat in HL, without severe
toxicity (Carlo-Stella et al. 2008).
HDACis in the treatment of acute myeloid leukemias
and myelodysplastic syndromes
The anti-leukemic activity showed in the preclinical studies
opened the way to a large number of clinical trials in
leukemia and myelodysplastic syndromes. Single agent
clinical trials proved to be interesting, but produced limited
results,possiblyduetothefactthatphaseIandIIclinicaltrials
enrolled refractory–relapsed, heavily pretreated patients.
The first HDACi used in the treatment of AML and high
risk MDS has been the valproic acid (VPA), a well-known
drug, used in the therapy of epilepsy. Most of the pioneer-
ing studies reported clinical efficacy of VPA alone, but
mostly in combination with all-trans retinoic acid (ATRA).
A pilot study of VPA/ATRA combination conducted in
11 elderly de novo AML patients (median age 82 years)
showed complete marrow response in three patients,
including one complete remission and two additional
hematological improvements (Raffoux et al. 2005).
A German clinical trial, studying the combination
VPA/ATRA, was also conducted in 26 poor-risk AML
patients; one patient with de novo AML, out of 19
evaluable for response, achieved a minor response, two
patients with AML secondary to myeloproliferative neo-
plasms reached partial response, while none achieved
complete remission (Bug et al. 2005).
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two differentiating agents, 13-cis retinoic acid and 1.25
dihidroxyvitamin D3 in 19 previously untreated MDS or
CMML patients, showed a response in three patients (16%),
although eight patients had to discontinue the treatment
for toxicity.
A phase II study has been conducted on 75 patients, 66
of which were treated with VPA monotherapy, in addition
to ATRA in non-responders or relapsed, and nine patients
were treated with ATRA+VPA from the beginning.
Response rates were disease-depending: 52% response in
MDS patients with normal blood count, 16% in AML, and
0% in CMML (Kuendgen et al. 2005).
Clinical evidences of the drug efficacy were shown in a
study conducted in 58 patients with AML (32 AML
secondary to MDS, 22 de novo AML, four AML secondary
to myeloproliferative neoplasms) elderly or medically unfit
to receive intense chemotherapy (Siitonen et al. 2007).
Twenty-seven patients received VPA+ATRA from the start,
and in 13 patients, ATRA was added later due to non-
responders or relapse. The response rate was only 5%, but
in 23 patients a decrease of blast count was observed
(Kuendgen et al. 2006).
A study conducted combining VPA with ATRA and
theophylline in 24 AML elderly patients showed that in 22
patientsevaluableforresponse,ninerespondedwithincreased
normal peripheral blood cell counts (Ryningen 2009).
The first evidence of the clinical efficacy of Vorinostat in
AML has been shown in patients with advanced hemato-
logical disease, where the vast majority was represented by
AML. Maximum tolerated dose was established as 200 mg
twice a day. Clinical response was observed just in patients
with AML, in terms of hematological improvement in 17%
of the cases, whereas two patients presented CR and two
CR with incomplete blood count recovery. None of the
patients with ALL, CLL, and MDS experienced any
response, despite hyperacetylation of histone H3 being
observed in the blood and bone marrow cells of all the
patients (Garcia-Manero et al. 2008a).
Panobinostat was also tested in the same category of
patients (AM, ALL, and MDS) in the first clinical trial,
administrated once a day intravenously, on day 1–7o na
21-day cycle. The trial was discontinued because it caused
asymptomatic QT elongation at the dose of 14 mg, but it
showed anti-leukemic activity in terms of reduction of
blasts number in the peripheral blood at all tested doses
(Giles et al. 2006).
Preliminary results from an ongoing phase IA/II dose
escalation study, with one arm receiving three times weekly
dosing and the other three times alternate weekly dosing.
Patients evaluable for response showed that anti-leukemic
activity was dose- and schedule-dependent, with no
response in patients treated alternative weekly, or those
treated at doses <40 mg, while two CR, one CR without
complete blood count reconstitution, and four patients with
>50% reduction bone marrow or peripheral blood blasts
(Ottmann et al. 2008).
Anti-leukemic activity has been reported in patients
treated with Mocetinostat. The drug has been readmitted
after suspension for episodes of pericarditis. A clinical trial
conducted in patients with AML and high risk MDS
reported three responses in AML patients, with two CR
(Garcia-Manero et al. 2008b), despite another trial carried
out on a less intensive regimen, which showed SD in four
of 19 treated patients (Lancet et al. 2007).
Entinostat has not shown encouraging results in 12
refractory AML patients, with no CR or PR, but just a
reduction in the blast count (Gojo et al. 2007). The study also
showed that the drug is not tolerable on a daily schedule.
Finally, Romidepsin was tested at the dose of 13 mg/m
2
once a week in a cycle of 4 weeks in a clinical trial that
divided patients with chromosomal abnormalities (known
to aberrantly recruit HDAC-repressive complexes) and
patients lacking in these abnormalities. Romidepsin showed
anti-leukemic activity in the cohort of patients carrying
chromosomal abnormalities that may recruit HDACs:
t(8;21), t(15;17) and inv16 (Odenike et al. 2008).
HDACis in the treatment of multiple myeloma
Several clinical trials have investigated the safety and
efficacy of some HDACis used as single agents in the
treatment of multiple myeloma (MM). The first study,
carried out with Vorinostat, was nearly terminated by
decision of the sponsor, and the MTD was not even found
(Richardson et al. 2008). Modest results have been
observed with panobinostat at the dose of 20 mg three
times a week (Niesvizky et al. 2005), and complete absence
of response in patients treated with Romidepsin was
reported (Wolf et al. 2008), whereas clinical response in a
clinical trial with Givinostat in 4 out of 14 patients was
reported (Galli et al. 2010)
An association study of Romidepsin in combination with
bortezomib in heavily pretreated myeloma patients has
shown good tolerability in the 22 patients treated, with four
CR, two VGPR, and six PR. The study is still ongoing
(Harrison et al. 2008), and a combination study of
bortezomib in combination with panobinostat is under
evaluation (Siegel et al. 2008).
Toxicity profile of HDACis
The primary aim of the epigenetic drugs is to target the
epigenetic HDAC-based alterations present in cancer,
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Drug Study Phase Disease NCT Status
Vorinostat (SAHA) A Study of the Efficacy of MK-0683 in Patients With
Polycythaemia Vera and Essential Thrombocythaemia
II PV NCT00866762 R
Vorinostat (SAHA) Study of Vorinostat (MK0683) With Follicular Lymphoma (FL),
Other Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) or
Mantle Cell Lymphoma (MCL) Patients
II FL_indolent
NHL MCL
NCT00875056 ANR
Vorinostat (SAHA) MK0683 Phase I Study in CTCL Patients I CTCL NCT00771472 ANR
Vorinostat (SAHA) Phase IIa Vorinostat (MK0683, SAHA) Study in Lower Risk
Myelodysplastic Syndromes
II MDS NCT00486720 C
Vorinostat (SAHA) A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in
Patients With Malignant Lymphoma
I Lymphoma NCT00127140 ANR
Vorinostat (SAHA) Compassionate Use of Vorinostat for the Treatment of Patients
With Advanced Cutaneous T-Cell Lymphoma
III CTCL NCT00419367 ANR
Vorinostat (SAHA) An Investigational Drug Study With Suberoylanilide Hydroxamic
Acid in Relapsed Diffuse Large B-cell Lymphoma
II DLBCL NCT00097929 C
Vorinostat (SAHA) Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced
Cutaneous T-cell Lymphoma
II CTCL NCT00091559 C
Vorinostat (SAHA) A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid
(SAHA) in Patients With Advanced Multiple Myeloma
I MM NCT00109109 C
Vorinostat (SAHA) Vorinostat in Treating Patients With Acute Myeloid Leukemia II AML MDS NCT00305773 C
Vorinostat (SAHA) A Study of the Efficacy of MK-0683 in Patients With
Polycythaemia Vera and Essential Thrombocythaemia
II PV and ET NCT00866762 R
CHR-2845 Safety and Tolerability of CHR-2845 to Treat Hematological
Diseases or Lymphoid Malignancies (CHR-2845-001)
I Lymphoid
Malignancies
NCT00820508 R
Pivanex A Pilot Study of Pivanex in Patients With Chronic
Lymphocytic Leukemia
II CLL, SLL NCT00083473 C
Resminostat (4SC-201) Resminostat (4SC-201) in Relapsed or Refractory Hodgkin’s
Lymphoma (SAPHIRE)
II HD NCT01037478 R
Panobinostat (LBH 589) Study of Oral LBH589 in Patients With Cutaneous T-cell
Lymphoma and Adult T-cell Leukemia/Lymphoma
II CTCL, T-ALL NCT00699296 C
Panobinostat (LBH 589) A Study of Oral LBH589 in Adult Patients With Advanced
Hematological Malignancies
I - II Lymphoma
Leukemia MM
NCT00621244 A N R
Panobinostat (LBH 589) Study of Oral LBH589 in Adult Patients With Refractory/
Resistant Cutaneous T-Cell Lymphoma
II - III PTCL; CTCL NCT00490776 C
Panobinostat (LBH 589) Panobinostat in Treating Patients With Relapsed or Refractory
Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
II Leukemia NCT00723203 R
Panobinostat (LBH 589) Panobinostat in Treating Patients With Relapsed or Refractory
Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
II ALL; AML NCT00723203 R
Panobinostat (LBH 589) Safety and Efficacy of Panobinostat in Patients With Primary
Myelofibrosis
II MMM NCT00931762 R
Panobinostat (LBH 589) A Phase III Randomized, Double Blind, Placebo Controlled
Multi-center Study of Panobinostat for Maintenance of
Response in Patients With Hodgkin’s Lymphoma
III HL NCT01034163 ANR
Panobinostat (LBH 589) Phase II Study of Oral Panobinostat in Adult Patients With
Relapsed/Refractory Classical Hodgkin’s Lymphom
II HL NCT00742027 ANR
Panobinostat (LBH 589) Panobinostat in Treating Patients With Relapsed or Refractory
Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
II ALL NCT00723203 R
Panobinostat (LBH 589) Study of Oral LBH589 in Adult Patients With Refractory
Cutaneous T-Cell Lymphoma
II - III CTCL NCT00425555 ANR
Panobinostat (LBH 589) Efficacy and Safety of LBH589B in Adult Patients With
Refractory Chronic Myeloid Leukemia (CML) in Accelerated
Phase or Blast Phase (Blast Crisis)
II - III CML NCT00449761 C
Panobinostat (LBH 589) Study of Oral LBH589 in Patients With Cutaneous T-cell
Lymphoma and Adult T-cell Leukemia/Lymphoma
II CTCL NCT00699296 C
Panobinostat (LBH 589) LBH589 in Relapsed or Relapsed and Refractory Waldenstrom’s
Macroglobulinemia
II WM NCT00936611 R
Panobinostat (LBH 589) Efficacy and Safety of LBH589 in Adult Patients With Refractory
Chronic Myeloid Leukemia (CML) in Chronic Phase
II - III CML NCT00451035 C
Panobinostat (LBH 589) Oral LBH589 in Relapsed or Refractory CLL and MCL II CML CLL NCT01090973 R
Panobinostat (LBH 589) Study of Oral LBH589 in Adult Patients With Refractory/
Resistant Cutaneous T-Cell Lymphoma
II - III CTCL NCT00490776 C
Belinostat (PXD101) Belinostat in Relapsed or Refractory Peripheral T-Cell
Lymphoma (PTCL)
II PTCL NCT00865969 R
Belinostat (PXD101) Clinical Trial of PXD101 in Patients With T-Cell Lymphomas II CTCL; PTCL; HD NCT00274651 A N R
Belinostat (PXD101) PXD101 in Treating Patients With Myelodysplastic Syndromes II MDS NCT00357162 R
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Belinostat (PXD101)) Belinostat in Relapsed or Refractory Peripheral T-Cell
Lymphoma (PTCL)
II PTCL NCT01016990 R
Givinostat (ITF2357) Phase II High Pulse Dose Clinical Trial of Orally Administered
ITF2357 In Patients With Relapsed/Refractory Multiple
Myeloma
II MM NCT00792506 ANR
Givinostat (ITF2357) Ph II Study of an HDAC Inhibitor in Very High-Risk
Relapsed/Refractory Hodgkin’s Lymphoma Patients
I - II HD NCT00496431 R
Givinostat (ITF2357) Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With
JAK-2 V617F Positive Chronic Myeloproliferative Diseases
II MPD (JAK2-
V617F +)
NCT00606307 C
Givinostat (ITF2357) Phase II Study of Histone-Deacetylase Inhibitor ITF2357 in
Refractory/Relapsed Lymphocytic Leukemia
II CLL NCT00792831 C
Givinostat (ITF2357) Phase II Study of GIVINOSTAT (ITF2357) in Combination With
Hydroxyurea in Polycythemia Vera (PV)
II PV NCT00928707 R
Romidepsin (FK228) FR901228 in Treating Patients With Relapsed or Refractory
Non-Hodgkin’s Lymphoma
II Lymphoma NCT00077194 C
Romidepsin (FK228) FR901228 in Treating Patients With Relapsed or Refractory
Non-Hodgkin’s Lymphoma
II Lymphoma NCT00383565 ANR
Romidepsin (FK228) A Single Agent Phase II Study of Romidepsin (Depsipeptide,
FK228) in the Treatment of Cutaneous T-cell Lymphoma
II CTCL NCT00106431 C
Romidepsin (FK228) A Trial of Romidepsin for Progressive or Relapsed Peripheral
T-cell Lymphoma
II PTCL NCT00426764 ANR
Romidepsin (FK228) Topical Romidepsin in Treating Patients With Stage I or Stage II
Cutaneous T-Cell Non-Hodgkin’s Lymphoma
I CTCL NCT00477698 R
Romidepsin (FK228) FR901228 in Treating Patients With Relapsed or Refractory
Multiple Myeloma
II MM NCT00066638 ANR
Romidepsin (FK228) FR901228 in Treating Patients With Hematologic Cancer I Leukemia
Lymphoma NCT00024180 C
Romidepsin (FK228) FR901228 in Treating Patients With Myelodysplastic Syndrome,
Acute Myeloid Leukemia, or Non-Hodgkin’s Lymphoma
II AML,ALL,MDS,
MM,MPN
NCT00042822 C
Romidepsin (FK228) FR901228 in Treating Patients With Relapsed or Refractory Acute
Myeloid Leukemia
II AML NCT00062075 ANR
JNJ-26481585 A Safety and Dose-finding Study of JNJ-26481585 for Patients
With Advanced of Refractory Leukemia or Myelodysplastic
Syndrome.
I AML, ALL;
CML; MDS;B-
CLL
NCT00676728 R
Mocetinostat (MGCD0103) A Phase I Study of MGCD0103 Given Three Times Weekly In
Patients With Leukemia Or Myelodysplastic Syndrome
I AML MDS NCT00324129 C
Mocetinostat (MGCD0103) A Phase I Study of MGCD0103 Given Twice Weekly in Patients
With Leukemia or Myelodysplastic Syndromes
I AML MDS NCT00324194 C
Mocetinostat (MGCD0103) A Phase I/II Study of MGCD0103 With Azacitidine in Patients
With High-Risk Myelodysplastic Syndrome (MDS) or Acute
Myelogenous Leukemia
I II MDS AML NCT00324220 C
Mocetinostat (MGCD0103) MGCD0103 in Elderly Patients With Previously Untreated AML/
High Risk MDS or Adults With Relapsed/Refractory Disease
II MDS AML NCT00374296 C
Mocetinostat (MGCD0103) Study of MGCD0103 Given Three Times Weekly in Patients With
Relapsed and Refractory Lymphoma
II HL NHL NCT00359086 C
Mocetinostat (MGCD0103) MGCD0103 in Elderly Patients With Previously Untreated AML/
High Risk MDS or Adults With Relapsed/Refractory Disease
II MDS AML NCT00374296 C
Mocetinostat (MGCD0103) Study of MGCD0103 Given Three Times Weekly in Patients With
Relapsed and Refractory Lymphoma
II NHL HL NCT00359086 ANR
Mocetinostat (MGCD0103) A Phase II Study of MGCD0103 (MG-0103) in Patients With
Refractory Chronic Lymphocytic Leukemia
II CLL NCT00431873 C
Mocetinostat (MGCD0103) Study of MGCD0103 (MG-0103) in Patients With Relapsed or
Refractory Hodgkin’s Lymphoma
II HL NCT00358982 C
Entinostat (MS 275) MS-275 in Treating Patients With Hematologic Cancer I Hematological
cancers
NCT00015925 C
Entinostat (MS 275) A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in
Patient With Relapsed or Refractory Hodgkin’s Lymphoma
II HL NCT00866333 R
R recruiting, C completed, ANR active, not recruiting; MDS myelodysplastic syndromes, AML acute myelogenous leukemia, T/B-ALL acute
lymphoblastic leukemia (T- or B-cell), HD Hodgkin disease, NHL non-Hodgkin lymphoma, DLBL diffuse large B-cell lymphoma, FL follicular
lymphoma, CTCL cutaneous T-cell lymphoma, CLL chronic lymphocytic leukemia, SLL small lymphocyte lymphoma, MCL mantle cell
lymphoma, PTCL peripheral T-cell lymphoma, CML chronic myelogenous leukemia, MPN myeloproliferative neoplasm, WM Waldenstrom
macroglobulinemia, MM multiple myeloma, PV policytemia vera, ET essential thombocytemia, MMM myelofibrosis with myeloid metaplasia
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Drug Study Phase Disease NCT Status
vorinostat bortezomib Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo
in Combination With Bortezomib in Patients With Multiple
Myeloma
III MM NCT00773747 R
Sorafenib-Vorinostat Combination of Sorafenib and Vorinostat in Poor-risk
Acute Myelogenous Leukemia (AML) and High Risk
Myelodysplastic Syndrome (MDS)
I AML MDS NCT00875745 R
Vorinostat,Bortezomib Phase 1 Study of Vorinostat and Bortezomib in Multiple
Myeloma
I MM NCT00111813 ANR
SAHA+CHOP SAHA+CHOP in Untreated T-cell Non-Hodgkin’s Lymphoma I II NHL NCT00787527 R
Lenalidomide, Vorinostat and
Dexamethasone
Lenalidomide, Vorinostat and Dexamethasone in Relapsed
Patients With Peripheral T-Cell Non-Hodgkin’s Lymphoma
(PTCL) (LenVoDex)
I II PTCL NCT00972842 R
vorinostat bortezomib Study of Vorinostat (MK0683), an HDAC Inhibitor, in
Combination With Bortezomib in Patients With Relapsed or
Refractory Multiple Myeloma
II MM NCT00773838 R
Vorinostat
CyclophosphamideEtoposide,
Prednisone, Rituximab
Trial of Vorinostat in Combination With Cyclophosphamide,
Etoposide, Prednisone and Rituximab for Elderly Patients
With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
II DLBCL NCT00667615 R
vorinostat bortezomib Combination of Vorinostat and Bortezomib in Relapsed or
Refractory T-Cell Non-Hodgkin’s Lymphoma
II DLBCL NCT00810576 R
Vorinostat+Pegylated Liposomal
Doxorubicin
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or
Refractory Lymphomas
I II Lymphoma NCT00785798 R
Vorinostat and Decitabine Vorinostat and Decitabine in Treating Patients With Advanced
Solid Tumors or Relapsed or Refractory Non-Hodgkin’s
Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic
Leukemia, or Chronic Myelogenous Leukemia
I NHL, AML,ALL
CML
NCT00791011 R
AMG 655, Bortezomib,
Vorinostat
Phase 1b Lymphoma Study of AMG 655 in Combination With
Bortezomib or Vorinostat
I NHL, AML,ALL
CML
NCT00791011 R
Vorinostat, Azacitidine Vorinostat in Combination With Azacitidine in Patients With
Newly-Diagnosed Acute Myelogenous Leukemia (AML) or
Myelodysplastic Syndrome (MDS)
II MDS NCT00948064 R
Vorinostat,Gemtuzumab,
Ozogamicin,Idarubicin
Cytarabine
Vorinostat Combined With Gemtuzumab Ozogamicin,
Idarubicin and Cytarabine in Acute Myeloid Leukemia
II AML NCT01039363 R
Vorinostat, Melphalan, Prednisone Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in
Advanced, Refractory Multiple Myeloma Patients
I II MM NCT00857324 R
Bortezomib and Vorinostat Bortezomib and Vorinostat as Maintenance Therapy After
Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma
II NHL NCT00992446 R
Vorinostat Lenalidomide,
Bortezomib Dexamethasone
A Study of the Combination Vorinostat With Lenalidomide,
Bortezomib and Dexamethasone for Patients With Newly
Diagnosed Multiple Myeloma
I MM NCT01038388 R
Vorinostat, Niacinamide,
Etoposide]
A Study to Evaluate the Use of the Drug Combination
Vorinostat, Niacinamide, and Etoposide in Patients With
Lymphoid Malignancies That Have Reoccurred
II Lymphoid
Malignancies
NCT00691210 R
Vorinostat, Idarubicin, Cytarabine II Study of Idarubicin, Cytarabine, and Vorinostat With
High-Risk Myelodysplastic Syndrome (MDS) and Acute
Myeloid Leukemia (AML)
II MDS AML NCT00656617 R
Vorinostat and Azacitidine Vorinostat and Azacitidine in Treating Patients With
Myelodysplastic Syndromes or Acute Myeloid Leukemia
I II MDS AML NCT00392353 R
Vorinostat, Gemtuzumab
ozogamicin, Azacitidine
Vorinostat, Gemtuzumab Ozogamicin, and Azacitidine in
Treating Older Patients With Relapsed or Refractory Acute
Myeloid Leukemia
I II AML NCT00895934 R
Vorinostat, Cytarabine, and
Etoposide
Vorinostat, Cytarabine, and Etoposide in Treating Patients With
Relapsed and/or Refractory Acute Leukemia or
Myelodysplastic Syndromes or Myeloproliferative Disorders
I AML, MDS, MPN NCT00357305 R
Vorinostat, Decitabine Phase I Trial of Vorinostat (MK0683, SAHA) in Combination
With Decitabine in Patients With AML or MDS.
I AML MDS NCT00479232 ANR
Vorinostat, Gemtuzumab
ozogamicin,
Vorinostat and Gemtuzumab in Treating Older Patients With
Previously Untreated Acute Myeloid Leukemia
II AML NCT00673153 R
Vorinostat, Bortezomib,
Doxorubicin
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride
Liposome in Treating Patients With Relapsed or Refractory
Multiple Myeloma
I MM NCT00744354 R
Vorinostat, Cladribine, Rituximab Vorinostat, Cladribine, and Rituximab in Treating Patients With
Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or
Relapsed B-Cell Non-Hodgkin Lymphoma
I II MCL, CLL, NHL NCT00764517 R
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Drug Study Phase Disease NCT Status
Vorinostat, Rituximab, Ifosfamide,
Carboplatin, Etoposide
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide
in Treating Patients With Relapsed or Primary Refractory
Lymphoma or Previously Untreated T-Cell Non-Hodgkin
Lymphoma or Mantle Cell Lymphoma
I II Lymphoma NCT00601718 R
Vorinostat, Rituximab +/- CHT Vorinostat, Rituximab, and Combination Chemotherapy In
Treating Patients With Newly Diagnosed Stage II, Stage III,
or Stage IV Diffuse Large B-Cell Lymphoma
I II DLBCL NCT00972478 R
Vorinostat, Fludarabine
Cyclophosphamide, Rituximab
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and
Rituximab in Treating Patients With Previously Untreated
B-Cell Chronic Lymphocytic Leukemia or Small
Lymphocytic Lymphoma
II B-CLL, SLL NCT00918723 R
Vorinostat Cytarabine Vorinostat and Low Dose Cytarabine for High Risk
Myelodysplasia (GFMVOR2007)
I II MDS NCT00776503 R
Vorinostat Rituximab Vorinostat and Rituximab in Treating Patients With Indolent
Non-Hodgkin Lymphoma
II NHL NCT00720876 R
Bortezomib Vorinostat Bortezomib and Vorinostat in Treating Patients With Recurrent
Mantle Cell Lymphoma or Recurrent and/or Refractory
Diffuse Large B-Cell Lymphoma
II MCL DLBCL NCT00703664 R
Vorinostat Lenalidomide VorinostatandLenalidomideAfterAutologousStemCellTransplant
in Treating Patients With Persistent Multiple Myeloma.
I MM NCT00729118 R
Vorinostat Lenalidomide
Dexamethasone
Vorinostat (MK0683, SAHA)+Revlimid+Dexamethasone in
Multiple Myeloma
I MM NCT00642954 ANR
Flavopiridol Vorinostat Flavopiridol and Vorinostat in Treating Patients With Relapsed
or Refractory Acute Leukemia or Chronic Myelogenous
Leukemia or Refractory Anemia
I AML CML MDS NCT00278330 ANR
Bortezomib Vorinostat Bortezomib and Vorinostat in Treating Patients With High-Risk
Myelodysplastic Syndrome or Acute Myeloid Leukemia
II MDS AML NCT00818649 ANR
Vorinostat bexarotene An Investigational Study of a Histone Deacetylase (HDAC)
Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma
Patients
I CTCL NCT00127101 R
Dasatinib Vorinostat Dasatinib and Vorinostat in Treating Patients With Accelerated
Phase or Blastic Phase Chronic Myelogenous Leukemia or
Acute Lymphoblastic Leukemia
I CML ALL NCT00816283 R
Decitabine, Vorinostat CHT Decitabine, Vorinostat, and Combination Chemotherapy in
Treating Patients With Acute Lymphoblastic Leukemia or
Lymphoblastic Lymphoma That Has Relapsed or Not
Responded to Treatment
II CML ALL NCT00882206 R
Vorinostat Bortezomib Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
(COMBOSTAT)
II NHL NCT00837174 R
Panobinostat and Everolimus Panobinostat and Everolimus in Treating Patients With
Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or
Hodgkin Lymphoma
I II MM NHL HL NCT00918333 R
Panobinostat Bortezomib
Dexamethasone
Panobinostat or Placebo With Bortezomib and Dexamethasone
in Patients With Relapsed Multiple Myeloma
III MM NCT01023308 R
Panobinostat LBH589 Plus I II MDS AML NCT00691 R
Decitabine Decitabine for Myelodysplastic Syndromes or Acute
Myeloid Leukemia
938
Panobinostat Imatinib LBH589 and Imatinib in Treating Patients With Previously
Treated Chronic Phase Chronic Myelogenous Leukemia
I CML NCT00686218 R
Panobinostat Bortezomib Panobinostat/Velcade in Multiple Myeloma I MM NCT00891033 R
Panobinostat Everolimus Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients
With Relapsed and Refractory Lymphoma
I II NHL NCT00967044 R
Bortezomib, Panobinostat Study of Bortezomib and Panobinostat in Treating Patients
With Relapsed/Refractory Peripheral T-cell Lymphoma or
NK/T-cell Lymphoma
II PTCL NCT00901147 R
Panobinostat,, bortezomib,
dexamethasone
Efficacy of Panobinostat in Patients With Relapsed and
Bortezomib-refractory Multiple Myeloma (PANORAMA II)
II MM NCT01083602 R
Panobinostat, Ara-C,Mitoxantrone A Phase Ib, Open-label, Multi-center Dose-finding Study of
Oral Panobinostat (LBH589) in Combination With Ara-C and
Mitoxantrone as Salvage Therapy for Refractory or Relapsed
Acute Myeloid Leukemia
I AML NCT01055483 R
Panobinostat 5-Azacytidine Dose-Finding Study of Panobinostat Given in Combination
With 5-Azacitidine in Patients With Myelodysplastic
Syndromes (MDS), Chronic Myelomonocytic Leukemia
(CMML) or Acute Myeloid Leukemia (AML)
I MDS, CMML,
AML
NCT00946647 R
38 Clin Epigenet (2010) 1:25–44leading to a better outcome with possibly a minimal
toxicity. The HDACis tested at the present in clinical trials
have shown to be safe, although adverse events, sometimes
severe, have been reported.
The most common toxicities have been related to
gastrointestinal or constitutional symptoms, hematologic
abnormalities (Pohlman etal.2009), or taste disorders (Bates
et al. 2010) and were mostly mild to moderate in severity. A
dose escalating study of Vorinostat in 41 patients AML was
recently reported. Grade 3/4 adverse events were predom-
inantly fatigue, diarrhea, and thrombocytopenia.
One of the first clinical studies conducted with
Panobinostat administered intravenously in patients with
AML, ALL, and MDS was suspended for the asymptomatic
grade 3 Fredericia correction factor (QTcF) prolongations
reported (Giles et al. 2006); further trials of the drug
Table 3 (continued)
Drug Study Phase Disease NCT Status
Melphalan Panobinostat Melphalan and Panobinostat in Treating Patients With Recurrent
Multiple Myeloma
I II MM NCT00743288 R
Panobinostat +/- EPO BH589 Alone or in Combination With Erythropoietin
Stimulating Agents (ESA) in Patients With Low or Int-1 Risk
MDS (GEPARD)
II MDS NCT01034657 R
Panobinostat Decitabine LBH589 Plus Decitabine for Myelodysplastic Syndromes or
Acute Myeloid Leukemia
I II AML MDS NCT00691938 R
GIVINOSTAT (ITF2357)+
hydroxyurea
Phase II Study of GIVINOSTAT (ITF2357) in Combination
With Hydroxyurea in Polycythemia Vera (PV)
II PV JAK2 + NCT00928707 R
5 azacytidine - Valproïc
acid- Retinoic acid
5-Azacytidine Valproic Acid and ATRA in AML and
High Risk MDS
II AML MDS NCT00339196 R
Entinostat Azacitidine MS-275 and Azacitidine in Treating Patients With
Myelodysplastic Syndromes, Chronic Myelomonocytic
Leukemia, or Acute Myeloid Leukemia
I MDS CMML AML NCT00101179 ANR
Entinostat, GM-CSF A Phase II Study of MS-275, in Combination With GM-CSF
Treating Relapsed and Refractory Myeloid Malignancies
II MDS NCT00466115 R
Entinostat ± Azacitidine Azacitidine With or Without MS-275 in Treating Patients
With Myelodysplastic Syndromes, Chronic Myelomonocytic
Leukemia, or Acute Myeloid Leukemia
II MDS AML CMML NCT00313586 R
Entinostat, GM-CSF MS-275 and GM-CSF in Treating Patients With
Myelodysplastic Syndrome and/or Relapsed or Refractory
Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
II AML ALL MDS
MPN
NCT00462605 R
Mocetinostat Azacitidine Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs
Combination in Elderly Subjects With Newly Diagnosed
Acute Myeloid Leukemia (AML) or Myelodysplastic
Syndrome (MDS)
II AML MDS NCT00666497 C
Mocetinostat Azacitidine MGCD0103 Administered in Combination With Azacitidine
(Vidaza®) to Subjects With Relapsed or Refractory Hodgkin
or Non-Hodgkin Lymphoma
II NHL HL NCT00543582 C
Mocetinostat Azacitidine A Phase I/II Study of MGCD0103 With Azacitidine in Patients
With High-Risk Myelodysplastic Syndrome (MDS) or Acute
Myelogenous Leukemia
I II AML MDS NCT00324220 R
Belinostat Bortezomib A Phase II Study of Belinostat in Combination With
Bortezomib in Patients With Relapsed, Refractory Multiple
Myeloma
II MM NCT00431340 ANR
Belinostat Dexametasone Clinical Trial of PXD101 in Patients With Advanced Multiple
Myeloma
II MM NCT00131261 C
Belinostat and Azacitidine PXD101 and Azacitidine in Treating Patients With Advanced
Hematologic Cancers or Other Diseases
I Hematological
neoplasms
NCT00351975 R
Romidepsin Bortezomib
Dexametasone
A Phase I/II Trial of Romidepsin (Depsipeptide) and
Bortezomib in Patients With Relapsed Myeloma
I II MM NCT00431990 R
Romidepsin Fludarabine
Rituximab
R901228 Alone or Combined With Rituximab and Fludarabine
in Treating Patients With Relapsed or Refractory Low-Grade
B-Cell Non-Hodgkin’s Lymphoma
I II NHL NCT00079443 C
Cytarabine, all-trans retinoic acid,
valproic acid
Combined Therapy With Valproic Acid, All-trans Retinoic Acid
(ATRA) and Cytarabine in Human Acute Myelogenous
Leukemia (AML)
I II AML NCT00995332 R
R recruiting, C completed, ANR active, not recruiting; MDS myelodysplastic syndromes, AML acute myelogenous leukemia, T/B-ALL acute
lymphoblastic leukemia (T- or B-cell), HD Hodgkin disease, NHL non-Hodgkin lymphoma, DLBL diffuse large B-cell lymphoma, FL follicular
lymphoma, CTCL cutaneous T-cell lymphoma, CLL chronic lymphocytic leukemia, SLL small lymphocyte lymphoma, MCL mantle cell
lymphoma, PTCL peripheral T-cell lymphoma, CML chronic myelogenous leukemia, MPN myeloproliferative neoplasm, WM Waldenstrom
macroglobulinemia, MM multiple myeloma, PV policytemia vera, ET essential thombocytemia, MMM myelofibrosis with myeloid metaplasia
Clin Epigenet (2010) 1:25–44 39conducted in lymphoma patients reported hyperglycemia,
fatigue, diarrhea, and thrombocytemia (Ellis et al. 2008).
Also Romidepsin has shown cardiac toxicity (Kim et al.
2008), which requires intensive electrocardiogram and
ejection fraction monitoring of patients receiving the drug,
along with careful patient selection excluding those with a
significant cardiac history, and the use of aggressive
electrolyte replacement to reduce risks of QTcF prolonga-
tion. Although minor electrocardiogram changes are rela-
tively frequent, the raised cardiac enzymes or altered left
ventricular function due to drug administration have been
reported thus far, even with prolonged treatment. Several
episodes of pericarditis or pericardial effusion in MGCD0103
trials have been also reported (Bociek et al. 2008;C r u m p
et al. 2008a; Garcia-Manero et al. 2008), decreasing the
clinical interest for this drug. Patients with no signs or
symptoms suggestive of pericardial disease are still in trials.
Other reported toxicities of MGCD0103 include fatigue and
gastrointestinal symptoms, with apparently lower hemato-
logic toxicity than other HDACis reported thus far.
Conclusions
The analysis of the clinical trials based on HDACis
confirmed the anticancer activity in hematological malig-
nancies. HDACis showed very encouraging results in the
treatment of CTCL and PTCL, although alternate results
have been reached in leukemia, where the drugs did not
dramatically change the outcome of the disease, when used
as single agent. However, nearly all the completed trials
have been conducted on refractory–relapsed heavily treated
patients, where adjunctive molecular changes and mecha-
nisms of drug resistance might have occurred, has to be
considered.
Another reflection is that all HDACis have been tested
without having a “rea” molecular biomarker of response.
Note that hyperacetylation of histones has been suggested
as one of the biomarkers of drug activity, despite the levels
of hyperacetylation do not seem to correlate with the
clinical response. In contradiction, constant hyperacetyla-
tion has been reported to correlate with a prolonged
response in lymphomas (Bates et al. 2010).
On a different angle, all the studies analyzed in this
review have been conducted using the HDACis as single
agents even if with different schedules, but combination
studies have just been completed or are ongoing (Tables 2
and 3), and might suggest interesting options for treatment.
What might be the next step?
Based on these evidences, the directions are clear. First
of all, it will be necessary to identify a biomarker predictive
of response to the therapy with HDACis thus helping
in stratifying the patient to the correct treatment. This
unfortunately has not yet been clearly identified (Stimson
and La Thangue 2009; Prince et al. 2009).
Note that very recently HR23B has been suggested as a
marker of response in CTCL (Khan et al. 2010). Moreover,
the administration schedule allowing a persistent hyper-
acetylation might be an option in selected cases. Finally, in
the combination studies, it will be significant to discrimi-
nate the “best” exact regimen of HDACis and chemother-
apy in time frames, doses, and drugs.
A better understanding of the mechanism of action of
HDACis will improve their use in clinical practice,
identifying the “right” disease, the “correct” patient, and
both the best combination and way of combination of drugs
to be applied.
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